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The Central Illustration displays the conceptual hypothesis for the current study. At near normal (high) FFR values, event rates should be lowest and the risk of PCI or CABG offers no or even negative net benefit (3, 4) . At lower FFR values tracking with reduced flow capacity, event rates should increase, and revascularization provides growing benefit (5) . Between the extremes of FFR, the 2 survival curves cross, thereby defining an outcomes-based FFR threshold for treatment decisions without reference to noninvasive tests or other surrogate criteria. imputation was not used due to the sizable number of missing fields for covariates with a statistically or clinically insignificant association with FFR.
For the patient-level meta-analysis, length of follow-up was also heterogeneous. Therefore, we primarily performed a time-to-event analysis using a Cox proportional hazards model. However, to examine the dependence of our findings on the specific model, we also entered binary events within 12 months into a logistic regression model. For both Cox and logistic models, the optimal outcomes-based threshold was determined from the coefficients as the intersection of the unrevascularized and revascularized fitted curves. Initially, the model only included the lesion-specific FFR value, revascularization as a binary variable, and an interaction term. Next, the model was expanded to adjust for percent diameter stenosis in the subset of lesions with that information.
The size of the patient-level data allowed for exploration of several important subsets. We repeated the previous analysis for the following subgroups: left main lesions, acute coronary syndromes (unstable angina and acute MI), known diabetes mellitus, graft conduits (internal mammary arteries, free radial vessels, and saphenous veins), and instent restenosis. Abbreviations as in Figure 1 . Figure 1 summarizes the published data search and study inclusion leading to a total of 9,173 (study-level) and 6,961 (patient-level) lesions. Table 2 for results from other models. FFR ¼ fractional flow reserve; MI ¼ myocardial infarction.
JACC VOL. 64, NO. 16, 2014 Johnson et al. Figure 3A shows the normalized 1-year MACE rate from the study-level meta-regression. The optimal FFR threshold for a composite of death, MI, and revascularization occurred at 0.75, rising to 0.90 after Poisson adjustment for variable length of follow-up, suggesting a sensitivity to how events are temporally distributed after the procedure. Figure 3B META-ANALYSIS OF STRATEGY-BASED STUDIES. Table 3 summarizes the 10 studies totaling more than 15,000 patients that compared an FFR-assisted revascularization strategy to one that only used anatomy. Whereas an FFR-assisted strategy led to treatment roughly half as often as an anatomy-based strategy, it not only lowered MACE by at least 20% but also provided superior angina relief of at least 10%.
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DISCUSSION
We demonstrated that FFR provides a continuous and independent marker of subsequent MACE as modulated by treatment (medical therapy vs. revascularization) in a broad range of clinical scenarios comprising thousands of patients from more than 12 countries and spanning more than 15 years of publications. Both the study-level analysis in Figure 3A and patient-level analysis in Figure 3B support the conceptual hypothesis proposed in the Central Illustration. Therefore, FFR can be seen not only as a physiologic "biomarker," because of its continuous and independent relationship to outcomes, but also as a target for treatment because revascularization alters the outcome curve.
As a clear corollary from the conceptual curve in the Central Illustration, revascularization offers a greater absolute benefit for more severe FFR values.
Close to either side of the FFR threshold, the net benefit or risk from PCI or CABG therapy remains small. By analogy to the idea of "tailored treatment"
for disease spectrums such as hypercholesterolemia (7), FFR provides the clinician with an objective tool to personalize risk/benefit tradeoffs continuously instead of in binary fashion. Our data support the concept that ischemia exists not as a dichotomous state, but rather as a graded continuum.
The FFR distributions in Figure 2 Figure 3 and Table 2 , a range of plausible FFR thresholds exists in our data depending on the clinical endpoint, statistical model, patient versus population analysis, and subgroup. However, our results can be used to enrich revascularization benefit when using FFR either for clinical care or in future research trials.
In the lesion-level FFR histogram in Figure 2B Because our analysis draws from the existing FFR literature, its findings parallel but extend and integrate prior publications with new insights on the continuous spectrum of FFR and its outcomes. The conceptual curve in the Central Illustration for FFR appears similar to work using nuclear perfusion imaging (9) in that "ischemia" by either technique relates continuously to outcomes as modulated by treatment (medical therapy vs. revascularization).
Preliminary results from the FAME-2 study (10) mirror the continuous relationship between FFR for untreated lesions and subsequent outcomes as seen in our Figure 3 . Additionally, the significant treatment interaction reported in the FAME-2 trial, showing larger benefit for PCI when FFR <0.65 and smaller benefit when FFR $0.65 (5), supports the similar threshold values found in our Table 2 . Both of these early findings from the FAME-2 trial will be clarified at completion of its primary 2-year endpoint analysis.
Therefore, patient-level FAME-2 trial data was excluded from this analysis (5).
STUDY LIMITATIONS. Similar to any meta-analysis, our study shares the limitations of its primary sources. Almost all of the study-and patient-level data comes from nonrandomized, observational designs.
Baseline characteristics reported in Table 1 Our analysis did not address in detail the amount of myocardium at risk distal to a lesion undergoing FFR measurement. We hypothesize that the same numeric FFR value has greater prognostic importance when the distal mass is large. Therefore, although the higher FFR threshold seen for left main stenosis in Table 2 makes intuitive sense, we could not explore the issue further due to lack of an angiographic risk score. 
